RecruitingNot ApplicableNCT07312513
Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds
Sponsor
Lohmann & Rauscher
Enrollment
104 participants
Start Date
May 9, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Debrisoft® Duo, to collect safety data regarding expected adverse events and to detect potential unexpected adverse events associated with the use of Debrisoft® Duo within the certified indications and under the conditions of routine use.
Eligibility
Min Age: 18 Years
Inclusion Criteria16
- Age ≥ 18 years
- Patient is legally capable
- Patient has signed written informed consent
- Presence of one of the following wounds
- Venous lower leg ulcer
- Arterial ulcer
- Diabetic ulcer
- Pressure ulcer
- Post-operative wound healing by secondary intention
- Traumatic wound
- Surgical wound
- Burn or scald (grade III: after surgical debridement)
- Epidermolysis Bullosa
- Wound area \>4cm2
- The entire wound area can be displayed on one photo from a distance of 25-30 cm
- Covered with at least 30% debris, necrosis, slough, fibrotic tissue
Exclusion Criteria11
- Known allergy and/or hypersensitivity to Debrisoft® Duo or any of the product components
- Pregnancy or breast feeding
- Patient is illiterate
- Participation in a interventional clinical trial within the last 14 days and during participation in this study
- Any other medical condition, which, by opinion of the investigator, may have impact of the success of the study treatment and/ or interpretation of the study results
- severe pain or hyperesthesia in the wound area
- history of drug or alcohol abuse
- chronic analgesic use (especially opioids) that could influence baseline pain perception
- cognitive impairment, which may affect the ability to accurately self-report pain
- Use of anaesthesia before the debridment procedure
- presence of hard necrotic tissue or other tissue which should not be debrided in general. Other types of hard necrotic tissue requiring debridement, as determined by the investigator, are permitted and may be also pre-moistened before the procedure if deemed necessary
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEtwo sided debridement pad
two sided debridement pad
DEVICEone sided debridment pad
one sided debridment pad
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07312513